<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511689</url>
  </required_header>
  <id_info>
    <org_study_id>RU-GAM-20-05-2020</org_study_id>
    <nct_id>NCT04511689</nct_id>
  </id_info>
  <brief_title>Comparative Study of Gene-activated Bone Substitute and Xenogenic Bone Matrix in Alveolar Ridge Augmentation</brief_title>
  <official_title>Comparative Study of Gene-activated Bone Substitute Based on Octacalcium Phosphate and Plasmid DNA Encoding VEGFA Gene and Xenogenic Bone Matrix for Alveolar Ridge Augmentation: an Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Histograft Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Histograft Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to compare the effectiveness of two bone substitutes, the gene-activated&#xD;
      bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene and&#xD;
      xemogenic deproteinized bone matrix, mixed with shredded autobone in vertical and horizontal&#xD;
      augmentation of alveolar ridge before dental implantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label randomized controlled clinical trial, two cohort. Patients who met the&#xD;
      inclusion criteria is planned to be enrolled into the trial. On enrollment, all patients will&#xD;
      have screening, a set of clinical examination, instrumental investigations and laboratory&#xD;
      tests, including dental CT of the affected jaw with the assessment of alveolar ridge width&#xD;
      and height.&#xD;
&#xD;
      All patients enrolled in the study will be subjected to guided bone regeneration surgery of&#xD;
      the upper or lower jaw with the use of investigational bone substitutes mixed with shredded&#xD;
      autobone harvested during the surgery. If the height of alveolar ridge needs to be augmented,&#xD;
      the non-resorbed systems for granular material fixation will be used.&#xD;
&#xD;
      The clinical study results will be evaluated at the time points of 1, 2, 10, 30, 90, and 180&#xD;
      days with clinical examination, instrumental investigations and laboratory tests. A control&#xD;
      dental CT will be carried out before dental implantation for the primary outcome measure, at&#xD;
      180 days after surgery. The clinical trial completion date is the day of the second surgery,&#xD;
      a dental implant placement. During the procedure, trephine biopsy samples will be harvested&#xD;
      from the bone grafting area addressing the secondary outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of soft tissues (fat and fibrous) with density less then 120 HU within total volume of tissues in the bone grafting area by CT scan</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of the total volume of tissues in the bone grafting area using manual segmentation tool and subsequent calculation of a proportion of the low-density tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>evaluation of the Adverse Events and Serious Adverse Events frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative pain level</measure>
    <time_frame>6 months</time_frame>
    <description>level of local pain assessed by Numeric rating scale (1-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative swelling level</measure>
    <time_frame>6 months</time_frame>
    <description>post-operative swelling level assessed by Numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>newly formed bone tissue level</measure>
    <time_frame>6 months</time_frame>
    <description>Volume of newly formed bone tissue in the trephine biopsy samples measured as a percentage of bone tissue in total square of histological slice</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alveolar Bone Loss</condition>
  <condition>Alveolar Ridge Pathology &amp;#X7C; Gingiva &amp;#X7C; Dental</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <description>bone grafting with gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>bone grafting with xenogenic deproteinized bone matrix mixed with autobone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gene-activated bone substitute mixed with autobone</intervention_name>
    <description>gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone</description>
    <arm_group_label>test group</arm_group_label>
    <other_name>xenogenic deproteinized bone matrix mixed with autobone</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are subjected to guided bone regeneration surgery of the upper or lower jaw&#xD;
        for subsequent dental implants placement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  partial or full edentulism;&#xD;
&#xD;
          -  alveolar ridge atrophy and defects preventing from dental implant placement;&#xD;
&#xD;
          -  obtained voluntary informed consent for participation in the clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  disability or unwillingness to give a voluntary informed consent or follow&#xD;
             requirements of the clinical trial;&#xD;
&#xD;
          -  plaque index (PI) score &gt; 15%;&#xD;
&#xD;
          -  gingival sulcus bleeding index (SBI) &gt; 10%&#xD;
&#xD;
          -  decompensated chronic diseases;&#xD;
&#xD;
          -  alcohol addiction;&#xD;
&#xD;
          -  a history of drug addiction;&#xD;
&#xD;
          -  a history of medication with drugs affecting bone tissue metabolism;&#xD;
&#xD;
          -  participation in other clinical trials (or the administration of investigational&#xD;
             products) within 3 months prior to the study;&#xD;
&#xD;
          -  conditions limiting study compliance (e.g., dementia, psycho-neurological diseases,&#xD;
             drug addiction, and alcoholism);&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grigory Volozhin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.I. Evdokimov Moscow State University of Medicine and Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.I. Evdokimov Moscow State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alveolar ridge atrophy</keyword>
  <keyword>bone grafting</keyword>
  <keyword>gene-activated matrix</keyword>
  <keyword>dental implants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alveolar Bone Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

